DW-MSC
- Generic Name
- DW-MSC
Therapeutic Study to Evaluate the Safety and Efficacy of DW-MSC in COVID-19 Patients
Phase 1
Completed
- Conditions
- Corona Virus InfectionSARCovid19
- Interventions
- Other: Placebo
- First Posted Date
- 2020-09-02
- Last Posted Date
- 2021-01-27
- Lead Sponsor
- Ina-Respond
- Target Recruit Count
- 9
- Registration Number
- NCT04535856
- Locations
- 🇮🇩
Site 550: University of Hassanudin/ Dr. Wahidin Sudirohusodo Hospital, Makassar, Indonesia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath